What Is Cisplatin Neuropathy and How Is It Managed?

Cisplatin neuropathy is nerve damage caused by cisplatin, a widely used platinum-based chemotherapy drug. It shows up primarily as numbness, tingling, and pain in the hands and feet, and it can persist for years after treatment ends. The condition affects the vast majority of patients receiving cisplatin at higher cumulative doses, and managing it remains one of the more frustrating challenges in cancer care because no drug reliably prevents it and only one medication has decent evidence for treating the pain it causes.

How Cisplatin Damages Nerves

Cisplatin works by binding to DNA inside cells, which is what makes it effective against tumors but also what makes it toxic to healthy tissue. The nerve cells most vulnerable are the sensory neurons in structures called dorsal root ganglia, clusters of nerve cell bodies that sit just outside the spinal cord. Cisplatin crosses into these neurons, binds to their nuclear DNA, and triggers a chain of events that leads to cell death.¹ Unlike many other cells in the body, mature sensory neurons do not regenerate easily, so the damage tends to accumulate with each treatment cycle.

Beyond direct DNA damage, cisplatin injures the mitochondria inside these nerve cells. Mitochondria are the energy-producing compartments that neurons depend on heavily, especially along the long axons running from the spine to the fingertips and toes. When mitochondria malfunction, the nerve fibers serving the hands and feet gradually die back, and the remaining neurons become abnormally excitable. That combination of nerve fiber loss and heightened nerve firing is what produces both the numbness and the pain that patients experience.²

What Cisplatin Neuropathy Feels Like

The hallmark pattern is a “stocking-glove” distribution: symptoms start in the toes and soles of the feet, then spread upward toward the ankles, while a similar process begins in the fingertips and moves toward the wrists.³ It is called “stocking-glove” because the affected area roughly matches where socks and gloves would sit. The neuropathy is overwhelmingly sensory rather than motor, meaning it attacks feeling rather than muscle strength. Common complaints include:

Numbness: A loss of sensation that makes it hard to feel textures, temperature, or even the ground underfoot.
Tingling and pins-and-needles: Persistent prickling sensations, often worse at night.
Pain: Burning, shooting, or electric-shock-like pain that can range from mild to debilitating.
Reduced coordination: Difficulty with fine motor tasks like buttoning a shirt or picking up small objects, driven by loss of sensation rather than muscle weakness.

Most patients who develop neuropathy during cisplatin treatment have mild to moderate symptoms. In one study of 67 patients receiving cisplatin, about 84% developed some degree of peripheral neuropathy, but roughly four out of five of those cases were graded as mild.⁴ Severe neuropathy was uncommon, though when it occurs it can be profoundly disabling.

The Coasting Effect

One of the most unsettling features of cisplatin neuropathy is that symptoms often continue to worsen for three to six months after the last dose of chemotherapy. This is called the coasting effect, and it happens because cisplatin accumulates in dorsal root ganglia and keeps damaging neurons long after infusions stop.⁵ Patients understandably find this alarming. They expect to start recovering once treatment is over, not to get worse. Anyone finishing a cisplatin regimen should be warned about coasting so they are not blindsided by it.

Coasting also complicates the clinical picture because it means oncologists cannot fully assess the final severity of neuropathy until several months post-treatment. Decisions about dose reductions or treatment switches need to account for the likelihood that whatever neuropathy exists at the end of chemotherapy is probably not the final state.⁶

What Raises the Risk

The single biggest predictor is cumulative dose. Cisplatin neuropathy is dose-dependent and accumulates over treatment cycles. Once the total dose crosses roughly 300 mg/m², symptoms become increasingly common, and above 600 mg/m², a substantial share of patients develop moderate or severe neuropathy.⁷ This is why oncologists track cumulative doses carefully and may switch to a different drug if the total climbs too high.

Body weight also appears to play a role. In the same study that found an 84% prevalence of neuropathy, almost all patients who were overweight or obese developed the condition.⁴ Pre-existing conditions that already stress peripheral nerves, like diabetes or heavy alcohol use, are recognized risk factors as well, though data on how much they add to the risk are hard to pin down precisely.

Genetic variation is another area of active research. Some studies have identified gene variants involved in the body’s oxidative stress defense that may influence susceptibility, though the findings have been borderline and difficult to replicate across large populations.⁸ Genetic testing to predict neuropathy risk before starting cisplatin is not yet standard practice.

How It Is Diagnosed

Diagnosis is largely clinical: a physician examines you, checks your reflexes, tests whether you can feel light touch and vibration in your hands and feet, and asks about symptoms. Standard nerve conduction studies, which measure how quickly electrical signals travel along nerves, are surprisingly limited here. Research has found that conventional nerve conduction tests are not more accurate than a thorough bedside exam for detecting cisplatin-related nerve damage. More sensitive methods, like short-latency somatosensory evoked potentials that measure signals traveling from the limb to the brain, appear better at catching early impairment.⁹

An emerging area involves blood-based biomarkers. Neurofilament light chain is a protein released into the bloodstream when nerve fibers are damaged. Studies on related platinum drugs have shown that blood levels of this protein rise during treatment and track with the severity of neuropathy.¹⁰ The hope is that monitoring this biomarker could eventually flag nerve damage before symptoms become obvious, giving clinicians a window to adjust treatment. So far, though, the evidence suggests the blood marker rises alongside symptoms rather than clearly preceding them, so it has not yet proven itself as an early warning tool.¹⁰

Can Anything Prevent It?

The honest answer is: nothing reliably works yet. A Cochrane systematic review examined a range of agents that have been tested as neuroprotective shields during cisplatin treatment, including amifostine, calcium and magnesium infusions, glutathione, vitamin E, and several others. None of them produced convincing protection when measured with objective, quantitative nerve function tests. Some showed modest, borderline-significant hints of benefit on subjective symptom scales, but the trials were small, the results inconsistent, and the review concluded that the evidence is insufficient to recommend any of them.¹¹

Cryotherapy, where cooling gloves and socks are worn during infusion to reduce blood flow to the extremities, is being investigated as a preventive approach. A large phase III trial is currently underway comparing cryocompression against other compression methods for preventing neuropathy during chemotherapy.¹² Until results are in, it remains experimental.

The most effective preventive strategy in current practice is dose management: monitoring for early signs of neuropathy at each treatment cycle and reducing the dose or switching agents before cumulative toxicity becomes irreversible. This is straightforward in principle but agonizing in practice, since the same cumulative doses that cause neuropathy are often the ones needed for the best cancer outcomes.

Treating the Pain With Medication

Duloxetine, an antidepressant that also modulates pain signaling, is the only drug with adequate evidence supporting its use for painful cisplatin neuropathy. The American Society of Clinical Oncology’s guideline on chemotherapy-induced neuropathy names duloxetine as the sole recommended pharmacological treatment, while noting that the benefit is limited in magnitude.¹³ In practice, oncologists typically start at a low dose and increase to about 60 mg daily, adjusting based on how well you tolerate it.¹⁴

“Limited benefit” does not mean no benefit. Many patients experience a meaningful reduction in pain, even if it does not disappear entirely. But the reality is that duloxetine takes the edge off rather than eliminating the problem. Other drugs commonly tried for nerve pain in general, such as gabapentin and pregabalin, are sometimes prescribed off-label for chemotherapy neuropathy, but the evidence base for them in this specific setting is weaker. Animal research has shown that pregabalin can reduce certain pain responses in cisplatin-treated rats, and it is used clinically when duloxetine is not enough or not tolerated, but robust human trial data supporting its efficacy for cisplatin neuropathy are lacking.¹⁵

Topical treatments like lidocaine patches or capsaicin cream are sometimes used for localized pain, though data supporting them come largely from other neuropathic pain conditions rather than cisplatin neuropathy specifically.

Exercise and Physical Rehabilitation

If there is a bright spot in the management landscape, it is exercise. A growing body of randomized trial evidence shows that structured exercise programs, particularly ones that include balance and sensorimotor training, produce meaningful improvements in function for people with chemotherapy-induced neuropathy. A meta-analysis of randomized trials found that exercise significantly improved balance in patients with neuropathy compared to control groups.¹⁶

What does this look like in practice? One randomized trial put cancer survivors with neuropathy through a program of balance exercises and endurance training. Participants who stuck with the program improved their ability to stand on one leg on an unstable surface, reduced their postural sway, and reported fewer motor symptoms.¹⁷ Another trial comparing sensorimotor and balance training to conventional physiotherapy found large improvements in balance, physical well-being, and overall quality of life in the group doing targeted balance work.¹⁸

Exercise does not regenerate damaged nerves. What it does is retrain the neuromuscular system to compensate for lost sensation, strengthen the muscles that stabilize joints, and improve proprioception, which is your body’s sense of where your limbs are in space. For people with numb feet who are at risk of falling, these are not trivial gains.

Other Non-Drug Approaches

Scrambler therapy is a newer approach that uses skin electrodes to deliver non-pain signals through the same nerve pathways that carry pain, essentially trying to override the pain message. A randomized trial comparing scrambler therapy to conventional transcutaneous electrical nerve stimulation (TENS) found that patients receiving scrambler therapy had at least a 50% improvement in neuropathy symptoms, outperforming TENS.¹² The approach is still considered investigational and is not widely available, but the early results have drawn interest.

Occupational therapy can also help with the practical side of numb fingers: adaptive tools for cooking and dressing, strategies to avoid burns or cuts when sensation is reduced, and hand exercises to maintain dexterity. These interventions do not show up as often in clinical trials, but they make daily life considerably easier for people living with significant neuropathy.

Long-Term Outlook and Recovery

The question most patients want answered, “will this go away?”, has a complicated answer. For mild cases, symptoms often improve over time, though the timeline is measured in months to years rather than weeks. For moderate to severe cases, recovery is slower and may be incomplete. A comprehensive review of the literature found that cisplatin neuropathy can persist for years and is associated with depression, insomnia, falls, and reduced quality of life in cancer survivors.¹⁹

One study that tracked patients after cisplatin and oxaliplatin treatment found that neuropathy in the hands recovered with a half-life of about seven years, meaning it took that long, on average, for symptoms to drop to half their peak severity. For the feet, no significant recovery was detected within the observation period at all.²⁰ Those numbers are sobering but important to know: patients and caregivers who set realistic expectations can plan accordingly rather than spending years waiting for a recovery that may not arrive in the way they hope.

Impact on Work and Daily Life

Cisplatin neuropathy is not just a medical problem; it is an economic and social one. A study of testicular cancer survivors found that those with severe neuropathy were roughly three times as likely to be on disability leave and about two-and-a-half times as likely to be unemployed compared to those without neuropathy. Pain, which was strongly correlated with neuropathy severity, amplified the effect further.²¹ Testicular cancer survivors are often young men in the prime of their working lives, so the vocational impact is especially sharp.

Falls are another underappreciated consequence. When you cannot feel the ground beneath your feet, uneven surfaces, stairs, and icy sidewalks become hazards. The resulting injuries can be serious, particularly in older survivors who may already have age-related balance challenges. Balance training, as discussed earlier, addresses this directly, and it is one of the strongest arguments for including structured exercise in any management plan. Even if the neuropathy itself does not improve dramatically, the functional adaptations from training can substantially reduce fall risk and maintain independence.